Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. This is an ASCO Meeting ...

A phase II study of erlotinib plus capecitabine (XEL) as first-line treatment for elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study). Background: Detecting epidermal growth ...

The new Omicron variant of coronavirus, with its many mutations and seemingly quick spread in South Africa, is worrying scientists and government officials. But doctors want to remind Americans that ...